Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

4 Biotech/Pharma Stocks To Watch

Published 01/10/2018, 12:03 PM
Updated 07/09/2023, 06:31 AM

Biotech and pharma stocks dominate our list of top charts to watch today.

  • Adamas Pharmaceuticals (NASDAQ:ADMS) moved up $1.72, or 5.3%, on Tuesday, closing at $33.87 on very light volume of 606,000 shares traded. Price has been volatile but has formed a bull flag consolidation pattern since the beginning of December. On Monday the company announced the full commercial launch of its Parkinson's drug, approved by the FDA in August for seven years of orphan drug exclusivity. With a close above the previous high of $38.22, the mid-$40s may not be far behind.
  • Collegium Pharmaceutical (NASDAQ:COLL) picked up 31 cents, closing at $18.49 on light volume of 337,800 shares traded Tuesday. The stock chart's On-Balance Volume indicator has held steady during the present bull wedge consolidation period, signaling that the stock has been accumulated during the past few months. Today the company announced closing of its agreement, initially announced last month, to license opioid Nucynta from Depomed (NASDAQ:DEPO), a move that Collegium's CEO said will help them achieve profitability faster. Next targets: $25 and $29.
  • Mirati Therapeutics (NASDAQ:MRTX) rocketed by 10.7%, up $1.85, closing at $19.05 on 501,500 shares traded Tuesday. The company announced Monday that BeiGene (NASDAQ:BGNE) will license the commercialization of Mirati's tumor drug in the Asia Pacific region. The stock has increased over 300% in value since mid-September. Price is now at resistance at $19.70. A close above that resistance level could open the door to the next targets at $22 and $24.
  • Nektar Therapeutics (NASDAQ:NKTR) exploded up $10.63, or 18.5%, to close at $68.03 on very heavy volume of 5.9 million shares traded Tuesday -- more than double its average daily volume. The move came with news that Nektar's CEO spoke positively at a conference about the company's cancer drug pipeline. The stock has gained an impressive 186% since the end of October. Next target: $80.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.